Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (http://nnw.fm/XeQG6). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!”
Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments”
POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines”
POAI subsidiary Helomics exec discusses the company’s quest to fight cancer Helomics tapping into the fast growing, billion-dollar AI in drug discovery market Pittsburgh-based company has been building foundational groundwork in cancer drug response profiling for two decades Helomics harnesses rich historic tumor data with the power of AI to test living tumor tissues Predictive … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s CIO Discusses Curing Cancer with AI on DojoLIVE! Interview”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment”
Predictive Oncology presenting at upcoming LD 500 investor conference Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Confirms Attendance at Upcoming LD 500 Microcap Investor Conference”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring to POAI more than a century of … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision”
Predictive Oncology Inc. (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Starts Presentation at The LD 500”
